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ARTICLE
Vascular RAGE transports oxytocin into the brain
to elicit its maternal bonding behaviour in mice
Yasuhiko Yamamoto1, Mingkun Liang2, Seiichi Munesue1, Kisaburo Deguchi3, Ai Harashima1, Kazumi Furuhara2,
Teruko Yuhi2, Jing Zhong2, Shirin Akther2, Hisanori Goto1, Yuya Eguchi1, Yasuko Kitao4, Osamu Hori4,
Yoshitake Shiraishi5, Noriyuki Ozaki5, Yu Shimizu1,6, Tomoya Kamide4,6, Akifumi Yoshikawa4,6,
Yasuhiko Hayashi6, Mitsutoshi Nakada6, Olga Lopatina2,7, Maria Gerasimenko2, Yulia Komleva7,
Natalia Malinovskaya7, Alla B. Salmina2,7, Masahide Asano8, Katsuhiko Nishimori9, Steven E. Shoelson10,
Hiroshi Yamamoto1,11 & Haruhiro Higashida2,7
Oxytocin sets the stage for childbirth by initiating uterine contractions, lactation and maternal
bonding behaviours. Mice lacking secreted oxcytocin (Oxt−/−, Cd38−/−) or its receptor
(Oxtr−/−) fail to nurture. Normal maternal behaviour is restored by peripheral oxcytocin
replacement in Oxt−/− and Cd38−/−, but not Oxtr−/− mice, implying that circulating oxcy-
tocin crosses the blood-brain barrier. Exogenous oxcytocin also has behavioural effects in
humans. However, circulating polypeptides are typically excluded from the brain. We
show that oxcytocin is transported into the brain by receptor for advanced glycation end-
products (RAGE) on brain capillary endothelial cells. The increases in oxcytocin in the
brain which follow exogenous administration are lost in Ager−/− male mice lacking RAGE,
and behaviours characteristic to abnormalities in oxcytocin signalling are recapitulated in
Ager−/− mice, including deﬁcits in maternal bonding and hyperactivity. Our ﬁndings show
that RAGE-mediated transport is critical to the behavioural actions of oxcytocin associated
with parenting and social bonding.
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Oxytocin mediates both physiological and psychosocialevents surrounding mammalian birth, including uterinecontractions, initiation of lactation, and maternal
bonding1,2. Oxytocin produced by oxytocinergic neurons in
hypothalamic paraventricular and supraoptic nuclei (PVN, SON)
has both central and peripheral actions, the latter through pos-
terior pituitary release into the circulation1–6. Systemic loss of
either oxytocin or oxytocin receptors (Oxt−/− and Oxtr−/−)
disrupts maternal nurturing behaviours in mice7,8. This is
restored by administration of exogenous oxytocin in Oxt−/− but
not Oxtr−/− mice, suggesting that peripheral oxytocin has
central effects. Mice lacking CD38, a cyclic ADP ribose synthetase
and hydrolase necessary for secretion of oxytocin, also display
this characteristic behavioural phenotype, which is also reversed
following administration of exogenous oxytocin5,9. Exogenous
oxytocin in humans also appears to have behavioural effects,
particularly in such social deﬁcit-related psychiatric disorders as
autism and schizophrenia9–13. Numerous clinical trials are
determining the psychopharmacological effects of peripherally
administered oxytocin in a variety of conditions14,15. The
potential for peripherally administered oxytocin to act centrally
is supported by measures of it in the brain. Oxytocin con-
centrations are maximal in human or primate cerebrospinal
ﬂuid (CSF) and mammalian hippocampus and amygdala within
10–60 min of peripheral administration16–19. Because many
peripheral peptides and proteins do not pass freely into the
central nervous system (CNS)20,21, we hypothesised a specialised
uptake mechanism for oxytocin to cross the blood-brain barrier
(BBB) and gain access to the CNS.
RAGE, a member of the immunoglobulin superfamily of pattern
recognition receptors, is not known to be related to oxytocin or
oxytocin signalling22–33. Full-length, membrane bound RAGE
(mRAGE) is present on many cell types. Endogenous soluble RAGE
(esRAGE), the product of an alternatively spliced mRNA, is found
in the circulation as it lacks a membrane-spanning domain29,34. A
second soluble form, ectodomain-shed RAGE (sRAGE), is a pro-
teolytic product of mRAGE28,30. The three RAGE forms bind
various ligands with similar afﬁnities, including multiple advanced
glycation end-products (AGEs) and amyloid β peptide31–37.
Here, our ﬁndings show that the expression of RAGE on
capillary endothelial cells of the blood-brain barrier (BBB) is
both necessary and sufﬁcient for the transport of oxytocin
into the brain. The increases in oxytocin in the brain which
follow exogenous administration are lost in RAGE knockout
male mice (Ager−/− mice lacking the mouse receptor for AGEs
gene). Behaviours characteristic to abnormalities in oxytocin
signalling are recapitulated in Ager−/− mice, including deﬁcits in
maternal bonding and hyperactivity, and both transport and
behavioural deﬁcits are restored in Ager−/− mice following
transgenic, endothelial cell expression of RAGE. These ﬁndings
indicate that RAGE-mediated transport can explain the degree of
brain oxytocin recruitment previously reported at the molecular
level, and demonstrate that oxytocin is critical to the behavioural
actions of oxytocin associated with parenting and social bonding.
Results
Oxytocin-RAGE interactions. Survival of Ager gene null
(Ager−/−) pups is often low due to maternal neglect, with even
mild maternal stress leading to dramatic reductions in offspring
survival (Fig. 1a). This is clearly a maternal deﬁcit, as newborn
Ager−/− pups transferred to wild-type (WT) post-partum
mothers are nurtured and survive at near normal frequencies.
By contrast, normal offspring of WT mothers do poorly when
transferred to post-partum Ager−/− mothers (Fig. 1b). Offspring
neglect in the absence of gross anatomic or histological defects
is a behavioural deﬁcit reminiscent of the characteristic disorders
seen with loss of oxytocin function, as in Oxt−/−, Oxtr−/− or
Cd38−/− mice5,7–9,38–40. Survival rates for Ager−/− pups fostered
by WT mothers were lower than for WT offspring raised by
their WT mothers, and survival rates for WT pups transferred
to Ager−/− mothers tend to be higher than for Ager−/− offspring
raised by their Ager−/− mothers (Fig. 1a, b). This too is seen
in Oxt−/−, Oxtr−/−, or Cd38−/− mice and attributable to
intrauterine and peripartum effects of loss of oxytocin function
occurring prior to the exchange of offspring. We therefore
hypothesised potential interactions between oxytocin and RAGE
signalling pathways.
Multiple methods were used to demonstrate direct binding
of oxytocin and RAGE. Surface plasmon resonance methods
showed concentration-dependent oxytocin binding to immobi-
lised recombinant esRAGE, with an apparent dissociation
constant (KD) of 179 nM (Fig. 1c). Oxytocin-RAGE binding
was further conﬁrmed using plate assays where either oxytocin
or esRAGE was immobilised, and esRAGE or oxytocin was in
solution, respectively (Fig. 1d, e).
Endogenous oxytocin and soluble RAGE also associate in
human circulation. Using gel permeation chromatography to
separate serum proteins based on molecular size, oxytocin
immunoreactivity co-eluted with soluble RAGE (Supplementary
Figure 1a). Larger amounts of free oxytocin eluted later, as
the molar amount of oxytocin in blood exceeds that of soluble
RAGE. Endogenous oxytocin in human serum (30 pmol/50 ml)
also co-eluted with soluble RAGE following isolation by anti-
RAGE antibody afﬁnity chromatography (Supplementary Fig-
ure 1b). Mass spectrometry was employed for further structural
identiﬁcation. In this case, we used immobilised esRAGE to
isolate oxytocin from 50ml human serum, and repeated the
procedure after adding a synthetic oxytocin standard (100 ng)
(Supplementary Figure 1c). Analyses of the eluted fractions by
liquid chromatography-tandem mass spectrometry (LC-MS/MS)
showed that endogenous oxytocin in human serum is structurally
indistinguishable from the synthetic oxytocin standard, as they
eluted at identical times (Supplementary Figure 1d) and have
identical parent ions (M+H+ 1008.2). Mass spectrometry of
the eluted material from the immobilised esRAGE did not
identify structurally related peptides such as arginine-vasopressin
which may cross-react in immunoassays.
Oxytocin binding to soluble RAGE suggests it also binds
membrane RAGE, but oxytocin neither stimulates a RAGE-
dependent NF-κB reporter nor inhibits reporter induction by
AGEs, a ligand that activates the NF-κB reporter22,27 (Supplemen-
tary Figure 2a). Furthermore, oxytocin did not activate NF-κB-
independent Rac1 or Cdc42 signalling, which are also suggested to
function downstream of RAGE24,41,42 (Supplementary Figures 2b
and 2c). Therefore, while oxytocin binds soluble and presumably
membrane RAGE, it neither induces nor inhibits intracellular
signals reported for RAGE ligands. Moreover, oxytocin binding
to soluble RAGE was weakly or non-speciﬁcally inhibited by
potential RAGE ligands: S100B, AGEs, amyloid β or high-mobility
group B1 (HMGB1)24,35,42 (Supplementary Figures 3a–d).
To further explore potential oxytocin-RAGE binding modes,
we subdivided extracellular RAGE into its V, C1 and C2 domains.
S100B, AGEs, amyloid β, and HMGB1 all bind the RAGE V
domain24,28. Oxytocin binding to soluble RAGE was blocked by
addition of recombinant V domain, marginally inhibited by
C1 domain, and not blocked by C2 domain (Supplementary
Figure 3e), suggesting that oxytocin binds the V domain, but at
a distinct site from S100B, AGEs, amyloid β or HMGB142,43.
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Oxytocin transport across the BBB. In vitro model systems are
used to predict the ability of compounds to cross into the CNS
and exert central effects44,45. We used one such system con-
structed using primary cultures of monkey brain capillary
endothelial cells (EC) coupled with rat pericytes and astrocytes to
assess requirements46 for endothelial RAGE in the transport of
oxytocin (Fig. 2a). Endothelial transport of oxytocin was dose-
dependent (Fig. 2b) and of a similar rate to transport of centrally
acting drugs46. RAGE was either left at endogenous levels or
reduced in the ECs by shRNA knockdown (Fig. 2c). The integrity
of the in vitro primate “BBB” was unaffected by RAGE knock-
down, assessed by high transendothelial electrical resistance
(TEER) (Fig. 2d). Notably, oxytocin transport was reduced
selectively in the blood-to-brain direction following RAGE
knockdown (Fig. 2b). Reverse transport was much less efﬁcient
(Fig. 2e), and according to calculated apparent permeability
(Papp) measures, inconsequential (Fig. 2f).
Immunohistochemical analyses showed RAGE in vascular
patterns limited to CD31 (platelet endothelial cell adhesion
molecule)-positive endothelial cells23, which are the components
of the BBB, of the hippocampus and choroid plexus of WT
(Fig. 3a, b) but not of Ager−/− mice (Supplementary Figure 4a).
We also performed confocal microscopic analyses to observe
RAGE expression in the circumventricular organs (CVOs) of
the brain, referred to as ‘windows of the brain’, and found that
RAGE expression was clearly observable in the endothelial cells
of the neurohypophysis (Supplementary Figure 4b), but barely
in those of the sensory CVOs, including the organum vasculosum
of the lamina terminalis, subfornical organ, and area postrema.
Further analysis revealed co-localisation of RAGE with cavelolin-
1, a marker of plasma membrane invaginations (caveolae), in
endothelial cells and the choroid plexus in WT mice
(Supplementary Figure 4c), suggesting a role of RAGE in the
oxytocin transfer (trafﬁcking) through caveolae-associated endo-
cytosis and transcytosis (Supplementary Figure 4d). By contrast,
oxytocin receptors, which could theoretically act as oxytocin
transporters, were not co-localised with endothelial cells in
numerous sections of 5 brain regions of Venus mice expressing a
ﬂuorescent oxytocin receptor reporter47 (Supplementary Fig-
ures 4e and f).
RAGE-dependent transport of oxytocin across the BBB. Oxy-
tocin concentrations in blood and CSF were assessed following
a subcutaneous injection of oxytocin (30 ng/mouse; approxi-
mately 1.1 μg/kg of body weight). Steady-state levels in
blood (~20 pg/ml) increased rapidly, peaking within 10 min
after injection and returning to baseline by 1–2 h in both WT and
Ager−/− male mice (Supplementary Figure 5a). By contrast, levels
of oxytocin in CSF from the cisterna magna of WT mice
increased more gradually to maxima at 1–2 h before returning to
baseline at 4 h (Fig. 4a). Despite equivalently high serum levels
following injection of identical amounts of oxytocin (Supple-
mentary Figure 5a), concentrations in the CSF of Ager−/− mice
remained at baseline levels (Fig. 4a).
In separate experiments we cannulated the third ventricles of
WT and Ager−/− mice and withdrew CSF for oxytocin
measurements. Following subcutaneous injection, oxytocin
increased in third ventricle CSF of WT but not Ager−/− male
mice (Fig. 4b and Supplementary Figure 5b). Microperfusion
methods showed that oxytocin also increased in relevant regions
of the brain, including the amygdala and PVN of the
hypothalamus, of WT but not Ager−/− male mice following
subcutaneous, intravenous or intranasal administration of
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Fig. 1 Offspring survival and RAGE-oxytocin interactions. Kaplan–Meier survival curves for offspring of WT (Ager+/+) and RAGE-null Ager−/− (knockout of
the mouse gene for the receptor for AGEs) dams housed with their biological mothers (a; n= 40WT pups/WT dams; 38 Ager−/−pups/Ager−/− dams), or
transferred to different cages and housed with postpartum dams of the opposite genotype (b; n= 66 WT pups/Ager−/− dams; 66 Ager−/− pups/WT
dams). P-values derived from log-rank calculations. c Surface plasmon resonance (BiaCore) assessment of oxytocin binding to immobilised human
esRAGE. d, e Microtitre plate wells contain varying amounts of immobilised oxytocin (d) or esRAGE (e); added d esRAGE (1 μg/ml) or e oxytocin
(100 μM) were detected immunochemically (n= 3). Values are mean ± SEM
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oxytocin but not saline carrier (Fig. 4c, d and Supplementary
Figure 5c). The direct CSF measures (Fig. 4a, b) and
microperfusion results (Fig. 4c, d) conﬁrm that oxytocin in the
blood is transported across the BBB as suggested by Landgraf
and his collegues16,17,20 and to our knowledge, show for the ﬁrst
time that endothelial RAGE is required for oxytocin transport
into the CNS.
Because this is such an important point, we further investigated
oxytocin transport following selective transgenic (Tg) expression
of RAGE in endothelial cells of both WT and Ager−/− mice using
an Flk-1 promoter26,41. Protein expression in both lines was
equivalent to the amount of endogenous endothelial RAGE
in WT mice (WT= 1, WT+ Tg~2, KO+ Tg~1). CSF concen-
trations were measured following subcutaneous injections of
oxytocin. Tg expression in Ager−/− mice increased oxytocin in
CSF to the WT concentration, whereas Tg expression in WT mice
minimally affected CSF oxytocin concentrations (Fig. 4e and
Supplementary Figure 5d). Stable isotope-labelled oxytocin was
used to more accurately assess transport into the CSF. Following
subcutaneous injection, [13C,15N]oxytocin was undetectable in
CSF of Ager−/− male mice, whereas amounts in the CSF of WT
or KO+ Tg mice were equivalent (Fig. 4f and Supplementary
Figure 5e). Although oxytocin has been found to produce sex-
speciﬁc effects48–50, RAGE-mediated oxytocin transport was also
observed in female WT-mice (Fig. 4g). These results demon-
strated that RAGE is both necessary and sufﬁcient for oxytocin
transport into the brain in both male and female mice.
Endothelial RAGE is upregulated in brain capillaries after
bilateral common carotid artery occlusion (BCCAO)23. Using
this method we found a ~2-fold increase in capillary RAGE
(Fig. 5a, b). We predicted this would also promote oxytocin
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Fig. 2 RAGE transports oxytocin across an in vitro blood brain barrier (BBB). a A schematic diagram of the monkey BBB kit (PharmaCo-Cell). EC, monkey
brain capillary endothelial cells; Peri, rat brain pericytes; Astro, rat astrocytes. The upper and the lower chambers represent the luminal (blood) and
abluminal (brain extracellular space) sides, respectively. b Oxytocin (1 or 10 ng/ml) was added to the upper (luminal, blood) chambers of the model BBB
system, and 3 h later oxytocin was quantiﬁed in the lower (abluminal, brain) chambers (n= 4–5). c Flow cytometry. The endothelial cells used in the upper
chamber in a were treated with RAGE shRNA (knockdown, KD) or control (C or CNT) vectors to assess the effects of RAGE knockdown. Isotype control
(Iso) instead of anti-RAGE antibody assesses background signal. d Transendothelial electrical resistance (TEER, Ωcm2) measures >150 Ωcm2 indicate
integrity of the model BBB (n= 6). e Conversely, oxytocin was added to the abluminal chambers and its transport to the luminal chamber was quantiﬁed
(n= 3). f The apparent permeability constants (Papp) for transfer were calculated from the distribution ratios across the chambers (n= 3–5). Values
are mean ± SEM
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ﬂuorescein to leak into the CSF (Fig. 5c), suggesting there is not
a generalised increase in vascular permeability. Nevertheless,
exogenous oxytocin increased in the CSF of WT but not Ager−/−
male mice after bilateral carotid occlusion (Fig. 5d and
Supplementary Figure 5f).
c-Fos as CNS actions of oxytocin. The classical studies of
Numan showed c-Fos positive neurons are activated during the
acquisition of postpartum maternal behaviours51. We utilised the
nuclear translocation of c-Fos as a readout for the neuronal
actions of oxytocin52, which are now known to activate c-Fos
positive neurons51–53. Numbers of c-Fos positive nuclei increased
after subcutaneous oxytocin administration in four distinct
regions of the brain, the bed nucleus of the stria terminalis
(BNST), medial preoptic area (mPOA), centre of the anterior
hypothalamic area (AHC) and ventral portion of the intermediate
lateral septal nucleus (ILS) (Fig. 6a, b). This is dependent on both
oxytocin and RAGE, as there are no effects in Ager−/− male mice
or when vehicle control was administered (Fig. 6b).
Maternal behaviour. Loss of maternal nurturing and social
interactive behaviours in Cd38−/− mice have been restored fol-
lowing peripheral administration of oxytocin, consistent with
transport of peripherally administered exogenous oxytocin into
brain5. We would not expect this to reverse the maternal bonding
deﬁcit in RAGE-null Ager−/− mice, as endothelial RAGE appears
to be required for CNS entry of peripheral oxytocin. Survival of
Ager−/− pups is often low due to maternal neglect, with even mild
maternal stress leading to dramatic reductions in offspring sur-
vival (Fig. 7a). However, our ﬁndings predict that restoration of
endothelial RAGE in Ager−/− mice would reverse the behavioural
phenotypes. There was a substantial rescue of the Ager−/− phe-
notype, as 63.4% of the transgenic Ager−/− (KO+ Tg) offspring
survived, compared to only 10.5% survival for the non-transgenic
Ager−/− (KO) offspring (P < 0.001) (Fig. 7a). Litters contained
both transgenic Ager−/− and non-transgenic Ager−/− offspring,
and all offspring were raised by their respective birth mothers. In
addition, offspring survival rate was lower in endothelial RAGE-
deﬁcient (EC-KO) mothers (P < 0.001; Fig. 7b).
Social behaviour in RAGE knockout mice. Clinical studies have
linked autism and Asperger’s disorders and attention-deﬁcit/
hyperactivity disorders to oxytocin deﬁciency7,8,54, and the
potential use of exogenous oxytocin to treat these conditions is
being assessed in clinical trials10,11,54–57. Ager−/− male mice are
also known to be hyperactive, with greater speeds and distances
travelled during both light-dark transition and open ﬁeld tests58.
These have been suggested to be potential mouse equivalents of
human anxiety properties. We therefore reasoned that the
hyperactivity seen in Ager−/− male mice might also be related to
a deﬁciency in transport of peripheral oxytocin into the CNS, and
administered exogenous oxytocin to WT and Ager−/− male mice.
Normal activity levels of WT mice were unaffected following
administration of either subcutaneous or intraventricular oxyto-
cin (Fig. 7c, d). By contrast, the elevated distances travelled
and average movement speeds of Ager−/− mice in light-dark
transition tests were normalised after intraventricular but not
subcutaneous administration of oxytocin. Concordantly, intra-
ventricular but not nasal administration of oxytocin normalised
distances travelled by Ager−/− mice in open ﬁeld tests (Fig. 7e).
These ﬁndings provide psychopharmacological support for the
importance of vascular RAGE-dependent transport of peripheral
oxytocin into the brain, which appears to be necessary for the
development and maintenance of normal social behaviours.
Discussion
Consistent with effects on maternal behaviour, mouse RAGE gene
ablation (Ager−/−) mice leads to maternal neglect and dramati-
cally decreased offspring survival. This phenotype is reminiscent
of mice lacking oxytocin (Oxt−/−) or with deﬁciencies in oxytocin
secretion (Cd38−/−) or action (Oxtr−/−)5,38,39. Notably, OT
release from the hypothalamus was not affected by the RAGE-
deﬁciency (Supplementary Figure 6). Supporting a primary role
for oxytocin transport by endothelial RAGE, selective transgenic
expression of RAGE in the endothelium of Ager−/− mice rescued
the maternal behaviour deﬁcit. The potential for RAGE to serve
as an oxytocin transporter is further supported by results from
our biochemical binding studies, the in vitro BBB model system,
where unidirectional blood to brain transport was seen, and
by measurements of oxytocin in various regions of the CNS of
WT and Ager−/− male mice before and after peripheral admin-
istration of oxytocin. Oxytocin concentrations were consistently
elevated in the third ventricle and cysterna as well as amygdala
and PVN of WT but not Ager−/− mice. c-Fos activation in
the mPOA and BNST is a classical maternal behavioural
response8,51, which was also recapitulated by exogenous oxytocin
administration in WT but not Ager−/− mice. These observations
of peripheral oxytocin effectiveness indicate that hypothalamic
oxytocin in Ager−/− mice was not sufﬁcient to induce maternal
behaviour, suggesting the importance of central release of oxy-
tocin stimulated by circulating oxytocin59.
The afﬁnity of oxytocin binding to the oxytocin receptor has
often been estimated to be KD ~100 nM, although a high afﬁnity
form with KD ~1 nM has also been reported60. Therefore our
























Fig. 3 RAGE in the brain vasculature. a, b Confocal microscopy. Sections of
the hippocampus (a; CA1, stratum radiatum) and choroid plexus in the third
ventricle (b) of WT male mice were immunostained with anti-RAGE and
anti-CD31 antibodies; nuclei were stained with DAPI (Bar= 100 μm). Co-
staining of RAGE (red, arrows) with CD31 (green) indicates that RAGE is
present in some vascular endothelial cells
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seems biologically reasonable. Under normal physiological con-
ditions the primary effects of oxytocin are peripheral, and the
endothelial RAGE transport system would not be engaged.
However, during childbirth when both peripheral and central
actions of oxytocin are needed, blood concentrations increase
dramatically, which may saturate peripheral receptor occupancy
and promote transport across the BBB. Levels of oxytocin in the
periphery are lower than those in the CSF, in humans16,61,62,
providing a concentration gradient for what appears to be a
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Fig. 4 Transport of oxytocin into the brain. a Oxytocin concentrations in CSF from the cisterna magna after subcutaneous injection of 30 ng oxytocin in
WT (Ager+/+) or Ager−/− male mice (n= 3–15/data point, *p < 0.05). b Oxytocin concentrations in the CSF of the third ventricles before and 90min
after subcutaneous administration of oxytocin (30 ng) (n= 7–9). c Oxytocin concentrations in microperfusates of the amygdala before and after intranasal
(20 ng) oxytocin. Closed circles, oxytocin in WT mice; open triangles, oxytocin in Ager−/− mice; inverted open triangles, saline in WT mice; open
squares, saline in Ager−/− mice (n= 4–13; *p < 0.05). d Oxytocin concentrations in microperfusates of the paraventricular nuclei (PVN) of WT mice before
and 60min after intravenous (iv), nasal (in) or subcutaneous (sc) administration of oxytocin (n= 6–8). e, f Transgenic (Tg) mice expressed human RAGE
selectively in endothelial cells either on WT or Ager−/− (KO) backgrounds. Oxytocin concentrations in the CSF were measured 60min after subcutaneous
injections of oxytocin (e; n= 4–14) or [13C,15N]oxytocin (f; n= 9–10). g Oxytocin concentrations in the CSF of female mice were measured 60min
after subcutaneous injections of oxytocin (OT) (n= 4–10). n.d., not detected; ns, not signiﬁcant. Values are mean ± SEM
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of oxytocin measurements in blood, because a recent report has
shown much higher blood OT levels than previously thought
using a robust nanoLC-MS platform63. Endothelial RAGE sig-
nalling is not required for the central actions of oxytocin, much
like the short form of the leptin receptor64. It remains unclear
how oxytocin is transported by RAGE on the capillary endothe-
lium. It is most likely that a vesicular trafﬁcking system, involving
endocytosis and transcytosis, a transcellular transportation across
endothelial cells, is involved in oxytocin transportation mediated
by RAGE carrier proteins65 (Supplementary Figure 4d).
Anterograde transport of oxytocin produced in the PVN and
SON of the hypothalamus leads to its accumulation in axon
terminals of the posterior pituitary, where it is released into
the systemic circulation. Surges in the release and circulating
concentrations of oxytocin occurring during childbirth activate
oxytocin receptors in the reproductive organs1,4, including
the uterus where oxytocin stimulates cervical dilation and uterine
contractions and the mammary glands to stimulate lactation.
Peripheral oxytocin may also act centrally to initiate maternal
bonding behaviours5,8. Pharmacological studies clearly show
that exogenous oxytocin has behavioural effects5,8–12,24,66,
which further demonstrates that peripheral oxytocin can act
centrally17,18. However, this has been a point of much debate and
dissension13,15,55,67, as polypeptides typically do not cross the
BBB without speciﬁc transport mechanisms20,45, and mechanisms
for oxytocin transport were unknown. Findings presented here
show that membrane-associated RAGE on endothelial cells
and potentially elsewhere in the CNS binds to and transports
peripheral oxytocin into the brain, as recently shown16–19,66.
It has been reported that intranasally administered oxytocin
may be transported to the olfactory nerve via olfactory sensory
neurons located in the mucous layer, or may reach the trigeminal
nerve via trigeminal ganglion cell ﬁbres, which are also located
close to the surface of the nasal cavity67,68. Unfortunately, current
experiments do not provide any evidence for such transport
mechanisms. However, capillaries are dense in the mucus mem-
brane, and thus the oxytocin can easily enter into the blood
stream17,68,69. Once nasally applied oxytocin is conveyed by the
blood stream, RAGE in the cerebral micro-vessels will transport
oxytocin into the brain. RAGE transport seems to be responsible
for the brain uptake of oxytocin nasally delivered oxytocin as
treatment for human ASD patients or administration of mega-
doses of pitocin during labour, which can potentially affect
maternal and foetal/newborn behaviour. Instead of direct nasal
transport bypassing the BBB, one of the main mechanism may be
uptake from the blood via RAGE, because rapid increases in
plasma oxytocin concentrations have been reported16; on the

















































































p < 0.04 p < 0.05
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Fig. 5 Oxytocin transport after transient brain ischaemia. a Transient brain ischaemia was induced by 15 min of bilateral common carotid arteries occlusion
(BCCAO) as described in Methods. RAGE and CD31 expression in vascular cells of the hippocampus were assessed 24 h after ischaemic insults; nuclei are
stained with DAPI (Bar= 100 μm). b Quantitation of RAGE induction in CD31-positive endothelial cells (n= 5). c Fluorescein dye was used to check
nonspeciﬁc vascular leakage and BBB damage following BCCAO (n= 3–6). ns, not signiﬁcant. d Oxytocin concentrations in CSF from the cisterna magna of
BCCAO or sham-operated WT (RAGE+/+) or Ager−/− male mice (n= 4–9). Values are mean ± SEM
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It has been reported that approximately 0.002% of the per-
ipherally applied amount of oxytocin (5 μg) reaches the CNS at
10 min after subcutaneous or intraperitoneal administration in
rats71, while the bioavailability is approximately 2% in rats, as
measured by LC/MS after administration of 500 μg oxytocin in
rats72. Rault et al. reported a bioavailability of 0.001% of i.n.
application of 50 μg oxytocin in female pigs18. With an intra-
carotid artery bolus injection of 125I-labelled or 3H-labelled
oxytocin, it was estimated that 1–2% of the oxytocin peptide
accumulated on the BBB in rats20. In our study, the estimated
availability of oxytocin in the CNF was 0.2%, after subcutaneous
administration of 30 ng oxytocin in mice, which was a much
lower amount of oxytocin than used in previous studies. The
ﬁndings on oxytocin reaching the CNS were inconsistent among
studies; this may be due to differences in treatment protocols,
species, and detection methods. Further studies are required to
determine the exact bioavailability.
The neural circuitry responsible for the peripartum acquisition
of maternal bonding behaviours in rodents and mammals more
generally is increasingly understood. Classical mapping studies
revealed roles for the mPOA and adjacent vBNST51–53,73,74.
Lesions in the mPOA identiﬁed important roles for dopaminergic
neurons projecting to the ventral tegmental area (VTA) involved
in reward and reinforcement learning51,53. Serotonergic signalling
is also critical for the acquisition of maternal behaviour, as
demonstrated by Pet1−/− mice with diminished serotonin
synthesis in the CNS75. The loss of maternal bonding by Pet1−/−
mice has been attributed to deﬁcits in the mPOA and BNST,
which are innervated by serotonergic neurons. oxytocin receptors
expressed in the mPOA and BNST are also critical for normal
maternal behaviour, which raises important questions about
sites of oxytocin expression and mechanisms of oxytocin supply.
Our ﬁndings suggest that peripheral oxytocin is transported by
RAGE into the CNS to activate oxytocin receptors directly.
Finally, there is precedence for RAGE to serve as a peptide
transporter across the BBB. For example, RAGE has been shown
to transport amyloid β peptide across the BBB, which promotes
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Fig. 6 Reporter assay for oxytocin activity in the brain. a 60min after sc administration of oxytocin (OT) (30 ng) or PBS, c-Fos positive nuclei were
visualised in the bed nucleus of the stria terminalis (BNST) of WT and Ager−/− male mice (LV, lateral ventricle; aca, anterior commissure, anterior part)
(Bar= 100 μm). b Densities of c-Fos positive nuclei in the BNST, medial preoptic area (mPOA), centre of the anterior hypothalamic area (AHC), and
intermediate lateral septal nucleus (ILS) regions of WT and Ager−/− mice (n= 12–56)
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also been implicated in the pathogenesis of diabetes complica-
tions. Since both of these are deleterious, pathological effects,
RAGE is being targeted for inhibition in drug discovery efforts35.
By contrast, our ﬁndings demonstrate that RAGE is required for
normal physiological functioning of oxytocin, which may also be
inhibited by these drug discovery strategies. Parental bonding and
nurturing and numerous other socially interactive behaviours are
promoted by oxytocin and may either be missing in its absence
or replaced by aggressive or anti-social behaviours.
Mass spectrometry of the eluted material from the immobilised
esRAGE in human serum did not identify arginine-vasopressin;
additionally, RAGE did not transport it in an in vitro blood–brain
barrier (BBB) assay system (Supplementary Figure 7). In con-
clusion, the contribution of peripheral oxytocin to centrally-
mediated behavioural actions has long been predicted76, and may
now be understood and studied more precisely in view of
the RAGE-mediated transport mechanism reported here. This
transport mechanism is not gender-speciﬁc, but equally function
in male and female mice (Fig. 4g).
Methods
Chemicals. Oxytocin was obtained from the Peptide Institute (Osaka, Japan).
Liquid chromatography mass spectrometer (LC-MS)-grade water, acetonitrile
(ACN), formic acid, triﬂuroacetic acid (TFA), and trichloroacetic acid (TCA) were
purchased from Wako Chemicals (Tokyo, Japan). Stably-labelled oxytocin
[13C,15N]oxytocin was synthesised using [13C5,15N1]-Pro7 and [13C6,15N1]-Leu8
(Scrum Co. Ltd., Tokyo, Japan), as described previously73.
Animals. RAGE knockout (Ager−/−, deletion of the mouse gene of the receptor for
AGE, Ager)41 and wild type (WT, RAGE+/+) mice (C57BL/6J) were produced by
crossbreeding heterozygous mutant mice27. Endothelial RAGE-transgenic (Tg)
mice26 were crossbred with Ager−/− mice to yield endothelial RAGE-Tg Ager−/−
mice (KO+ Tg). Both male and female mice were maintained under standard
cage conditions (24 °C; 12-h light/dark cycle, lights on at 8:45 a.m.) with sawdust
bedding, and food and water ad libitum. Breeding pairs were maintained in
separate cages. Offspring were weaned at 21 days of age and housed in same-sex
sibling pairs. For monitoring offspring survival, pregnant WT and Ager−/− mice
were transferred to a new environment (clean cages) 1 day before delivery. The
offspring were either kept with biological mothers or caged with postpartum
mothers of the alternative genotype. All animal experiments were approved by the
Committee on Animal Experimentation of Kanazawa University and performed
in accordance with the Fundamental Guidelines for Proper Conduct of Animal
Experiment and Related Activities in Academic Research Institutions under the
jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology
of Japan.
Chromatography. Polypeptides were separated using a Superdex 75 pg HiLoad
26/600 column (GE Healthcare Japan, Tokyo) eluted at 1.0 ml/min with 5 mM
ammonium acetate pH 7.8. Human serum (12 ml) preincubated with 48 ng oxy-
tocin was separated and an enzyme immunosorbent assay (EIA) was used to
identify OT in eluting fractions. Anti-RAGE monoclonal antibody (1.0 mg) or
puriﬁed esRAGE (0.5 mg) were coupled to NHS-activated HiTrap (GE Healthcare).
Sera samples (50 ml) from healthy consenting adults were applied to the HiTrap-
anti-RAGE column equilibrated with 50 mM Tris–HCl (pH 7.4) and 0.15 M NaCl.
Alternatively, the low molecular weight (<3000, Amicon Ultracel3K) fraction of
human serum (50 ml) was applied to the HiTrap-esRAGE column previously
equilibrated with phosphate-buffered saline (PBS). After washing the bound pro-
teins were eluted with 100 mM glycine-HCl buffer (pH 2.5) for HiTrap-anti-RAGE
or 10 mM Tris–HCl (pH 7.4) and 2.0 M NaCl for HiTrap-esRAGE and the eluates
were analysed by EIA or LC-MS/MS and Western blotting.
Surface plasmon resonance assay. Isolated human esRAGE was immobilised to
BIAcore CM5 research grade sensor chips with the amine coupling kit to a density
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Fig. 7 Offspring survival in Ager−/− mice and behavioural characteristic. a Survival curves for biological offspring of WT (Ager+/+) dams with (solid black
line, n= 45) or without (black dashed line, n= 40) re-expressed human RAGE (Tg). Survival curves for biological offspring of Ager−/− (KO) dams with
(red solid line, n= 71) or without (red dashed line, n= 38) re-expression of human RAGE. P < 0.001. b Survival curves for offspring of dams deﬁcient for
RAGE in endothelial cells (EC-KO, n= 76) and WT (Ager+/+) dams (solid black line, n= 45). P < 0.001. P-values derived from log-rank calculations. c, d
During light-dark transition tests, the greater distances travelled (c) and greater average speed (d) in the light zone exhibited by Ager−/− male mice were
both reduced by intraventricular (V) but not subcutaneous (sc) injection of oxytocin (OT) (n= 14–16). e In open ﬁeld tests that assess anxiety in a new
environment, the total distance travelled during the ﬁrst 5 min was determined for Ager−/− male mice before and after intraventricular (intraV) (5min, 0.1
ng/μl × 3 μl/min) or nasal (100 ng/ml × 20 μl) administration of oxytocin (OT) (n= 4–5). ns, not signiﬁcant. Values are mean ± SEM
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esRAGE was analysed using a BIAcore 2000 system (GE Healthcare Japan)27,32,41
and mobile phase 10 mM HEPES (pH 7.4), 0.15M NaCl, 3 mM EDTA and 0.005%
(V/V) surfactant P-20 at 25 °C and 20 μl/min. The sensor chips were regenerated
with 10 mM NaOH and 0.5% SDS (W/V).
Plate binding and competition assay. Oxytocin binding to RAGE and compe-
tition by RAGE ligands were assayed with oxytocin-coated 96-well plates, human
esRAGE, and horseradish peroxidase (HRP)-conjugated anti-human RAGE anti-
body27. Oxytocin (100 μl, indicated concentrations) was immobilised in 96-well
microtitre plates, 1 μg/ml esRAGE was added, and bound esRAGE was detected
immunochemically using covalently coupled 〈RAGE antibody- horseradish
peroxidise-catalysed oxidation of tetramethylbenzidine. RAGE ligands were S100B
(Sigma-Aldrich, St. Louis, MO, USA)30, AGE-BSA (glyceraldehyde-derived AGE-
BSA)27,32,41, amyloid β 1-42 (Sigma-Aldrich), and high-mobility group box 1
(HMGB1, Sigma-Aldrich)42.
Luciferase assay. C6 rat glioma cells expressing RAGE and stably transformed
with NF-κB promoter-driven luciferase constructs27,41 were incubated for 24 h
in Dulbecco’s modiﬁed eagle’s medium (DMEM) supplemented with 0.1% foetal
bovine serum (FBS) prior to 4 h stimulation with OT, S100B or AGE-BSA (gly-
ceraldehyde-derived AGE-BSA)32,41. The luciferase activities were assayed with
a Luciferase Assay System (Promega, Madison, MI, USA).
Mass spectrometry. High MW proteins in diluted mouse plasma were pre-
cipitated with 2% TCA; supernatants obtained after centrifugation were analysed
by LC-MS/MS. Mouse CSF samples diluted 1:5 with PBS (25 μl) were analysed
directly. Human plasma samples (50 ml) spiked with 100 ng of oxytocin and 75 ng
of [13C,15N]oxytocin were concentrated using immobilised esRAGE afﬁnity
chromatography. The eluting 1.0 ml fractions (Fig. 1h) were analysed by LC-MS/
MS. The 25 μl samples were separated using a ZORBAX 300SB-C8 column (2.1 ×
150 mm, 5 μm; CA, USA) eluted with a linear gradient of 0.1% (v/v) formic acid
and acetonitrile (0–30%) at 0.3 ml/min and 50 °C. Eluted proteins were detected in
the multiple reaction monitoring (MRM) mode of the MS/MS system (Shimazu
UFLC, Kyoto, Japan; AB Sciex 4000 QTRAP, Framingham, MA, USA; positive ion
electrospray (ESI) mode (capillary voltage 5 kV); desolvation voltage (75 V); cur-
tain gas (nitrogen, 12 l/h, 65 psi and 600 °C); nitrogen gas pressure (65 psi), and
collision voltage (30 V). Oxytocin MRM transition ions and fragment types were
m/z: 1008.2 → 723.2 (b6); and [13C,15N]oxytocin: m/z: 1021.2 → 723.2 (b6)73. Data
were acquired and processed with AB Sciex Analyst Version 1.4.1.
Blood-brain barrier (BBB) model. For the in vitro BBB model (MBT-24H,
PharmaCo-Cell Co., Nagasaki, Japan), rat brain pericytes (1.5 × 104 cells/cm2) and
rat astrocytes (1.5 × 104 cells/cm2) were seeded on the bottom of the collagen-
coated polyester membranes of Transwell inserts (Corning Life Sciences, MA,
USA). After 16 h the cells ﬁrmly adherent, monkey brain vascular endothelial cells
(1.5 × 105 cells/cm2) were then seeded on the upper side of the inserts in 24-well
culture plates. The in vitro BBB models were established within 4 days of seeding
the cells according to the manufacturer’s instructions46. Trans-endothelial electrical
resistance (TEER), which primarily reﬂects the ﬂux of sodium ions through the cell
layers in the culture conditions, was measured with an epithelial-volt-ohm metre
and an Endohm-6 chamber electrodes (World Precision Instruments, Sarasota, FL,
USA). The TEERs of the coated, cell-free ﬁlters were subtracted from the measured
TEER values of the models and shown as Ω cm2. The apparent permeability
constants (Papp) between luminal and abluminal chambers were calculated from
the distribution ratios46. Endothelial expression was silenced using RAGE shRNA
and the pSilencer 3.0-H1 vector (Ambion, Austin, TX, USA)41.
Flow cytometry. Isolated brain endothelial cells were washed and resuspended
in staining buffer (PBS containing 2% FCS) containing FcBlock (BD Biosciences,
San Jose, CA, USA). The cells were incubated with polyclonal rabbit anti-RAGE
antibody or isotype IgG (15 min at 4 °C in the dark)27 followed by anti-rabbit
IgG-FITC (eBioscience, San Diego, CA, UAS), and analysed by FACS AriaII (BD
Biosciences) and FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Immunohistochemical analysis. The hippocampus and choroid plexus were cut
into 10-μm-thick sections by using a cryostat. The sections were blocked in PBS
containing 0.3% TritonX-100 and 3% BSA for 1 h at room temperature, and
incubated at 4 °C overnight with primary polyclonal rabbit anti-RAGE antibody
(1:1000), anti-CD31 or anti-Caveolin 1 antibodies (Millipore, Billerica, MA, USA;
1:500) and 4′,6-diamidino-2-phenylindole (DAPI, Dojindo; Kumamoto, Japan,
1:2000) as previously described20. The sections were subsequently washed with
0.3% TritonX-100 in PBS and incubated with Alexa Fluor 488 (1:200, Invitrogen
Molecular Probes) and Cy3-labled-IgG (1:100, Jackson ImmunoResearch
Laboratories, PA) for 1 h at room temperature. Imaging was performed with a
Nikon EZ-C1 laser confocal microscope (Tokyo, Japan).
Sampling of the cerebrospinal ﬂuid (CSF) and blood. CSF was collected
according to the protocol for sampling CSF from mice without detectable plasma
contamination77,78. Under ketamine anaesthesia (100 mg/kg intraperitoneally), the
occipital skull was exposed, and the dura mater of the cisterna magna appeared as a
glistening and clear reverse triangle through which the medulla oblongata, a major
blood vessel (arteria dorsalis spinalis), and CSF space were visible. A capillary tube
was inserted into the cisterna magna through the dura mater, blood-free CSF
samples were collected with a 32G needle and immediately frozen with dry ice
prior to storage at −80 °C. After CSF collections, blood samples were obtained
by cardiac puncture from the mice under continuous ketamine anaesthesia.
Microperfusion. For microperfusion probe implantation79, the male mice were
with a subcutaneous injections of ketamine. The heads of anesthetised mice were
ﬁxed in a stereotactic frame (Narishige, Tokyo, Japan) and a 1 mm hole was drilled
in the skull. The intact dura intact was then punctured to create deﬁned opening of
the meninges. Using the stereotactic frame, a healing dummy was slowly inserted
into the three brain positions80. The probe was ﬁxed to the skull by using two
anchor screws and biocompatible dental cement. All surgical procedures were
completed within 30 min. A healing dummy was used to provide mechanical
stability during the implantation and the healing period of 2 weeks80. The
microperfusion probe (a 4-mm length of the coaxial tube, 2.5 mm in diameter)
consisting of a 20 G ﬂuorinated ethylene propylene guide cannula was replaced
before sampling with an inﬂow/outﬂow tubing on the day of the experiments80.
This tubing was connected to two glass Hamilton microsyringes placed in syringe
pumps (Eicom, Osaka, Japan). Microperfusate was pumped into the probe at a ﬂow
rate of 2 µl/min, and the samples were withdrawn at the same ﬂow rate. Sampling
was conducted for 2 h. Both microprobes were perfused without sampling for
60 min before the ﬁrst 30-min microperfusates from the amygdala, PVN, and
prefrontal cortex were collected. The microperfusates were mixed under sterile
conditions and consisted of 154 mM NaCl, 2.2 mM CaCl2, 5.6 mM KCl, 2.3 mM
NaHCO3, and 0.15% BSA (pH 7.4)80. Beginning immediately after the nasal
application, 4 additional microperfusates were taken at 30-min intervals. After the
termination of the experiments, the brains were removed and snap-frozen to obtain
40-μm cryo-cut stained brain slices later for the histological veriﬁcation of the
perfusion site.
Administration of oxytocin. Synthetic oxytocin (1000 ng/ml × 20 μl) was
administered nasally; the solution was applied bilaterally on the rhinarium, which
is the area referred to as the glaberous skin around the nostrils, using a pipette),
intravenously (100 ng/ml × 30 μl) through the tail vein, or subcutaneously
(100 ng/ml × 0.3 ml) into the shoulder skin. [13C,15N]oxytocin (100 μg/ml ×
0.3 ml) was subcutaneously injected.
Enzyme immunoassay for oxytocin. Oxytocin immunoreactivity levels in serum
and CSF were quantiﬁed by using an oxytocin EIA kit (Enzo Life Sciences, NY,
USA, formerly Assays Designs, MI, USA), following the manufacturer’s manual.
The CSF samples (5 μl) were thawed and diluted 1:20 in assay buffer77. CSF
samples were assayed without protein extraction due to the low protein con-
centration in the CSF. The plasma samples (100 μl) were thawed on ice and assayed
with protein extraction5,77, whereas an additional extraction step may have resulted
in lower than actual oxytocin levels. Each sample volume was so small, the CSF
was assayed without extraction, though unextracted samples result in binding of
complexes of oxytocin stuck to interacting proteins. The oxytocin assay had two
linear ranges, which covers a lower concentration range from a few to 30 pg/ml,
and a higher concentration range between 50 and 1000 pg/ml. The inter-assay and
intra-assay coefﬁcients of variation were less than 15%.
Oxytocin release from the hypothalamus. WT and Ager−/− male mice were
anaesthetised with pentobarbital sodium (50 mg/kg). The entire bilateral hypo-
thalami were obtained and placed separately in different wells of a 12-well plate
with 0.4 ml normal Locke’s solution (pH 7.25) containing 140 mM NaCl, 5 mM
KCl, 1.2 mM MgCl2, 2.2 mM CaCl2, 10 mM glucose, 10 mM HEPES, and 0.01%
BSA, in a 35 °C water bath. The incubation medium was replaced 10 times every
3 min, as described80. Beginning at the 11th replacement, the temperature was
shifted to 38.5 °C. From the 13th–15th replacements, cyclic ADP-ribose (a ﬁnal
concentration of 100 μM, Sigma) was added into the Locke’s medium at 38.5 °C.
Aliquots from the 8th replacement were preserved at −80 °C for assaying the
oxytocin concentrations released from the hypothalamus.
Light-dark transition test. The light-dark transition was used to examine the
anxiolytic-like or anxiogenic-like activity of the mice as previously described81.
The light-dark test chamber (200 mm × 600 mm × 200 mm) consisted of two
dividing rooms: a small dark (2 lux) safe compartment (one-third, 200 mm ×
200 mm × 200 mm—dark box) and a large brightly illuminated (250 lux) aversive
compartment (two-thirds, 400 mm × 200 mm × 200 mm—light box). The mice
were placed into the light arena and were allowed to move freely between the two
chambers for 600 s. Each male mouse was placed in the centre of the light chamber,
and the mouse was allowed to run freely between the two chambers for 10 min.
The trial was recorded for 10 min by using the ANY-maze video system (Stoelting
Co., Wood Dale, IL, USA). Latency to enter (deﬁned by all four paws entering),
time spent, entries, and distances travelled in the light chamber were recorded.
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A recovery test was performed following subcutaneous injection of oxytocin
(100 ng/ml × 0.3 ml) or intraventricular application of oxytocin (100 ng/ml) for 10
min at 2 μl/min, through implanted cannulae, as described above.
Open ﬁeld test. The open ﬁeld test is meant to assess anxious behaviour80. It
uses a wooden box (60 × 60 × 20 cm) covered with polypropylene and having an
outlined centre space (30 × 30 cm). Animal are in the box for 10 min, and their
movements into the centre are digitally recorded and analysed using ANY-maze
software. This test is based on the idea that mice naturally prefer to be near
protective walls rather than being exposed to potential dangers in open spaces. Test
chambers are cleaned after each trial.
Cerebral ischaemia model. WT and Ager−/− male mice (8 to 12-weeks-old and
weighing 20–30 g) were used for the experiments. The animals were anaesthetised
with 2.0% halothane and maintained with 0.5% halothane through a facemask.
Brain ischaemia was induced via bilateral occlusion of the common carotid arteries
(BCCAO) for 15 min using microvascular clips as described previously23. Laser-
Doppler ﬂowmetry was used to measure cerebral cortical microperfusion (3 mm
lateral to bregma). In our experimental model, the mice that exhibited <15% of the
baseline control microperfusion during the ﬁrst minute of occlusion were used in
subsequent experiments. Rectal temperature was maintained at 36.5–37.5 °C by
using a heat lamp and a blanket until the mice were completely alert. The control
animals underwent a sham-operation that was identical with the exception of the
occlusion. To quantify accumulative BBB leakages, 200 µl of sodium ﬂuorescein
(Sigma-Aldrich) at a concentration of 6 mg/ml in PBS was injected via the venous
sinus of retro-orbital in the mice. Sodium ﬂuorescein (MW 376.3) is a ﬂuorescent
tracer that does not cross an intact BBB. Sixty minutes later, the CSF and blood
were collected according to the protocol for sampling of CSF and blood from
mice80. The ﬂuorescence of CSF and serum were measured at 460 nm at an
excitation wavelength of 355 nm by using a Fluoroscan Ascent FL luminometer
(Labsystems. Wilmington, DE, USA). Results are presented as relative ﬂuorescence
units (CSF value/serum value) (%).
c-Fos activity. The c-Fos immunohistochemistry was performed as previously
described53. Brieﬂy, anesthetized male mice were intracardially perfused with cold
PBS followed by a cold 4% paraformaldehyde (PFA) in PBS. The brains were
removed and post-ﬁxed in a 4% PFA solution overnight at 4 °C. Brain regions were
cut into 2–4 large blocks. The blocks were sliced on a microtome into 20-μm-thick
sections. The sections were pre-incubated in blocking solution (3% bovine serum
albumin and 0.3% Triton X-100 in PBS) for 1 h, then incubated with an anti-c-Fos
antibody (sc-52, 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA) in the
blocking solution for 12 h at 4 °C. After three washes with washing buffer, the
sections were incubated with goat anti-rabbit IgG antibody coupled with Alexa
Fluor 488 (Invitrogen, Carlsbad, CA, USA) in the blocking solution for 1 h at room
temperature. The images were obtained by using an Olympus IX71 inverted
microscope equipped with a cooled CCD camera (Cool SNAP HQ2; Roper Sci-
entiﬁc, Tucson, AZ, USA). The number of c-Fos immuno-positive nuclei in each
brain section were recorded and analysed using Metamorph software (Molecular
Devices, Downingtown, PA, USA).
Immunoelectron microscopy. The immunogold staining method was applied to
the amygdala as previously described5. Brieﬂy, after 10min of oxytocin (100 ng/ml ×
0.3 ml) injection, wild type (WT, Ager+/+) and Ager−/− mice were perfused with a
mixture containing 2% paraformaldehyde and 2% glutaraldehyde solution in 0.1 M
phosphate buffer (pH 7.2). The tissue blocks were then ﬁxed by immersion for 4 h
at 4 °C in the same solution and washed for 1 h with 0.1 M phosphate buffer (pH
7.2). After washing, the tissue blocks were dehydrated and embedded in LR-White
resin (London Resin Co.). Ultrathin sections were mounted on nickel grids. The
sections were washed with PBS, incubated in a blocking solution of 1% bovine
serum albumin (BSA) and 0.05% sodium azide (NaN3) in PBS for 15 min, and then
exposed with anti-oxytocin polyclonal antibody (1:5000, Chemicon International,
Inc. USA) overnight at 4 °C. After washing twice with PBS, the sections were
incubated with 5 nm gold-conjugated goat anti-rabbit secondary antibody (1:100,
Sigma, USA) in a solution containing 0.1% BSA in PBS for 4 h at room tem-
perature. The sections were washed with PBS and then with distilled water. After
washing, the sections were stained with uranyl acetate and analysed under a
transmission electron microscope (Joel, Tokyo Japan) by using an 80-kV accel-
erating voltage.
Statistical analysis. P values were calculated by using two-tailed Student’s t-test
for pair wise comparisons, and one-way or two-way analysis of variance (ANOVA)
followed by Bonferroni’s or Tukey’s test for multiple comparisons, unless otherwise
stated. The Kaplan–Meier survival analysis was performed to compare survival
curves between the different groups of mice. A P-value of < 0.05 was considered
statistically signiﬁcant. Data are expressed as mean ± SEM. Statistical data with F
vales are shown in Supplementary Table 1.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the ﬁndings in this study are available from the corresponding
author upon reasonable request. The source data of each ﬁgure are presented as a
Supplementary Data 1.
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